产品封面图
文献支持

Human Coagulation Factor VIII

收藏
  • ¥9177 - 20800
  • Prospecbio
  • 以色列
  • pro-317
  • 2025年07月10日
    avatar
  • 企业认证

    点击 QQ 联系

    • 详细信息
    • 文献和实验
    • 技术资料
    • 保存条件

      for future use below -18°C

    • 保质期

      See instructions

    • 英文名

      F8

    • 库存

      常规产品有备货

    • 供应商

      上海经科化学科技有限公司

    • CAS号

    • 规格

      200IU/400IU/600IU

    规格:200IU产品价格:¥9177.0
    规格:400IU产品价格:¥15800.0
    规格:600IU产品价格:¥20800.0

    产品细节图片1

    CATALOGUE NUMBER

    PRO-317

    SYNONYMS

    Coagulation factor VIII, Procoagulant component, Antihemophilic factor, AHF, F8, F8C, F8B, HEMA, FVIII, DXS1253E, F8 protein.

    INTRODUCTION

    Coagulation factor VIII participates in the intrinsic pathway of blood coagulation; factor VIII is a cofactor for factor IXa which, in the presence of Ca+2 and phospholipids, converts factor X to the activated form Xa. This gene produces two alternatively spliced transcripts. Transcript variant 1 encodes a large glycoprotein, isoform a, which circulates in plasma and associates with von Willebrand factor in a noncovalent complex. This protein undergoes multiple cleavage events. Transcript variant 2 encodes a putative small protein, isoform b, which consists primarily of the phospholipid binding domain of factor VIIIc. This binding domain is essential for coagulant activity. Defects in this gene results in hemophilia A, a common recessive X-linked coagulation disorder.

    DESCRIPTION

    Human Factor VIII produced from Human Plasma contains 2332 amino acids and having a molecular mass of 330kDa. Factor-VIII is effective in the correction and prevention of severe bleeding episodes attributed to Factor VIII deficiency.

    The Factor-VIII is purified by proprietary chromatographic techniques.

    SOURCE

    Human Plasma.

    PHYSICAL APPEARANCE

    Sterile Filtered White lyophilized (freeze-dried) powder.

    FORMULATION

    The lyophilized protein 200IU/ml was lyophilized from a sterile solution containing 1.5% Glycine, 160mM Calcium chloride and 25mM NaCitrate and 25mM NaCl.

    SOLUBILITY

    It is recommended to reconstitute the lyophilized Factor-VIII in sterile 18MΩ-cm H2O at a concentration of 200IU/ml, which can then be further diluted to other aqueous solutions.

    Make sure that the vial has reached room temperature prior to its reconstitution, otherwise it might precipitate.

    STABILITY

    Lyophilized Factor-VIII although stable at room temperature for 1 week, should be stored desiccated between 2-8°C. Upon reconstitution Factor-VIII should be stored at 4°C.

    BIOLOGICAL ACTIVITY

    The potency was found to be 10 Units/mg.

    HUMAN VIRUS TEST

    The plasma is collected from donors with Hepatitis B vaccinated.

     Each unit of plasma has been tested for HBsAg, Anti-HIV-1/2 plus O and Anti-HCV by using the imported kits which are approved by Federal Drug Administration (FDA).

    SAFETY DATA SHEET

    SDS

    USAGE

    Prospec's products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.

    风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。

    图标文献和实验
    该产品被引用文献

    Human Factor VIII produced from Human Plasma contains 2332 amino acids and having a molecular mass of 330kDa. Factor-VIII is effective in the correction and prevention of severe bleeding episodes attributed to Factor VIII deficiency.

    The Factor-VIII is purified by proprietary chromatographic techniques.

    相关实验
    • Use of Human Hepatocytes to Investigate Blood Coagulation Factor

      is to describe experimental procedures allowing to measure the secretion by primary human hepatocytes and functional activity (including production of fibrillar material from extracellular medium) of haemostasis proteins including factors II, V, VII, VIII, PIVKA-II (protein

    • Nijmegen-Bethesda Assay to Measure Factor VIII Inhibitors

      Hemophilia A is an inherited bleeding disorder caused by a deficiency of factor VIII coagulant activity (FVIII:C). Patients are treated with infusions of either plasma-derived or recombinant factor VIII. However, some patients develop

    • Identification of Mutations in the Human Factor VII Gene

      It has been recognized from the early 1800s that activation of coagulation can be initiated by the exposure of subendothelial layers (tissue factor), but it was the 1940s before factor VII (FVII) was included in this event

    同类产品报价

    产品名称
    产品价格
    公司名称
    报价日期
    ¥21000
    上海经科化学科技有限公司
    2025年07月12日询价
    询价
    默瑞(上海)生物科技有限公司
    2025年07月14日询价
    ¥1934
    广州威佳科技有限公司
    2025年06月11日询价
    ¥17482.50
    北京孚博生物科技有限公司
    2025年07月16日询价
    ¥650
    南京北鱼生物科技有限公司
    2025年07月09日询价
    文献支持
    Human Coagulation Factor VIII
    ¥9177 - 20800